Finally, if the new phase 3 study (such as NCT03539744 with venetoclax) meets its objectives and confirms the results, BCL2 inhibitors should soon be able to be used in patients with relapsed multiple myeloma with t(11;14), and would then be the first targeted therapy to be approved on a biomarker in the myeloma field. Here, BCL2 is linked to plasma cell myeloma.